 |
||||||||
 |
|
 |
 |
 |
 |
 |
|
|
Active Portfolio - USAA B C D E F G H I J K L M N O P Q R S T U V W X Y Z HISTORY EUROPE PUBLIC |
||||
|
Aileron Therapeutics, Inc. is developing a revolutionary class of drugs called Stapled Peptides that represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. http://www.aileronrx.com |
|||
|
Alios BioPharma, Inc. is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system. http://www.aliosbiopharma.com/ |
|||
|
Anaphore, Inc. is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases. http://www.anaphoreinc.com |
|||
|
CalciMedica, Inc. is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company's drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels. http://www.calcimedica.com/ |
|||
|
CoNCERT Pharmaceuticals, Inc. creates new drugs by using precision deuterium chemistry to modify the pharmacology of existing and new small molecule compounds to create a treatment benefit. http://www.concertpharma.com/ |
|||
|
Constellation Pharmaceuticals, Inc. is the leading biopharmaceutical company dedicated to the development of novel therapeutics in the emerging area of epigenetics, a new field that describes how the selective regulation of chromatin state controls key cellular activities such as gene expression, cell fate decisions, and DNA damage repair. http://www.constellationpharma.com/ |
|||
|
Dicerna Pharmaceuticals, Inc. is a next generation RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules. http://www.dicerna.com/ |
|||
|
Genocea Biosciences, Inc. - commercializing key breakthroughs in vaccine discovery and development. http://www.genocea.com/ |
|||
|
HTG Molecular provides products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The Company's qNPATM molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue. http://www.htgmolecular.com/ |
|||
|
iPierian, Inc. is a leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell technology and directed differentiation of patient cells for the discovery and development of new therapeutics in neurodegenerative, metabolic and other diseases. http://www.ipierian.com/ |
|||
|
Locus Pharmaceuticals, Inc. applies its core fragment-based, computational drug design technology with its capabilities in medicinal chemistry, crystallography and biology to create small molecule product. The company has a portfolio of emerging candidates in development for cancer and inflammation. http://www.locuspharma.com/ |
|||
|
Nimbus Discovery LLC uses its privileged access to Schrödinger's cutting-edge computational chemistry technology to identify drug candidates against previously inaccessible biological targets. http://www.nimbusdiscovery.com/ |
|||
|
Novalar Pharmaceuticals, Inc. is a specialty pharmaceutical company.Lead asset NV-101, for the reversal of numbness associated with local dental anesthesia, has completed Phase III trials. An NDA was filed in 2007. http://www.novalarpharm.com/ |
|||
|
NeuroTherapeutics Pharma, Inc., or NTP, is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system (CNS) hyper-excitability. http://www.ntprx.com/ |
|||
|
Start up company focused on advancing best in class medicines in Immunology, Autoimmune Diseases and Oncology using proprietary chemistry platform. |
|||
|
Rib-X Pharmaceuticals, Inc. is developing novel classes of anti-microbials to address unmet needs in resistant community and hospital-acquired infections using structure-based drug design and its proprietary knowledge of the crystal structure of the 50S subunit of the ribosome and other important targets. http://www.rib-x.com/ |
|||
|
Scynexis, Inc. offers drug discovery and development services to biotech and pharmaceutical companies through a suite of research, development and products. http://www.scynexis.com/ |
|||
|
Semprus Biosciences is developing a surface technology platform that provides âtherapeutic-like benefitâ by simultaneous reduction in colonization and cell attachment for extended durations. http://www.semprusbio.com/ |
|||
|
SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. http://www.springleaftx.com |
|||
|
Synovex Corporation - developing novel antibody therapeutic for rheumatoid arthritis and other indications | |||
|
Zelos Therapeutics, Inc. is developing new treatments for osteoporosis and other indications based on breakthrough discoveries in parathyroid hormone research. Lead candidate Ostabolin C is in Phase II trials. http://www.zelostherapeutics.com/ |
|||